skulpt-collagen-peptides The dominant search intent for "peptide centric car" is to understand what peptide-centric chimeric antigen receptors (PC-CARs) are, how they function, and their applications, particularly in cancer therapy. The SERP results highlight their role in targeting intracellular oncoproteins that are typically inaccessible to traditional CAR T-cell therapies.
Tier 1: peptide centric car, PC-CARs, chimeric antigen receptors, intracellular oncoproteins, cancer therapy, targeting tumor cells, HLACAR-T Cells for Neuroblastoma using MHC Dextramer.
Tier 2: neuroblastoma, PHOX2B, KRAS, mutant KRAS, epitopes, peptides, T cells, CAR T-cell therapy, solid tumors, HLA restriction, cross-HLA targeting(PDF) Cross-HLA targeting of intracellular oncoproteins ....
Tier 3: Specific peptide sequences (eA roadmap for driving CAR T cells toward the oncogenic ....g以肽为中心的CAR实现细胞内肿瘤蛋白的交叉HLA靶向 - 新闻., QYNPIRTTF), specific HLA alleles (e.g.Retraction Note: Cross-HLA targeting of intracellular oncoproteins withpeptide-centric CARs. Nature. 2023-11;. Mark Yarmarkovich, Quinlen F Marshall, John M ..., HLA-A9), specific project names or Synapse IDs, retractions, computational modeling, counter panning strategy, scFvs, MHC dextramer.2025年4月14日—The ACGT-Barbara Netter Fund awards grant forpeptide-centric CART-cell therapy for neuroblastoma. · What is CAR T-cell therapy? T cells are a ...
---
Peptide-centric chimeric antigen receptors (PC-CARs) represent a significant advancement in the field of cancer immunotherapy, offering a novel approach to target intracellular oncoproteins. Unlike traditional CAR T-cell therapies that are limited to surface antigens, PC-CARs are engineered to recognize tumor-specific peptide epitopes presented on human leukocyte antigens (HLAs) on the cell surface.John Maris, MD: Translating peptide-centric CAR T cell ... This breakthrough allows for the targeting of previously unreachable intracellular cancer drivers, potentially expanding the scope of CAR T-cell therapy to a wider range of cancers.
At their core, PC-CARs are a type of engineered T cell designed to identify and eliminate cancer cells. The key innovation lies in their recognition mechanismThese antigens cannot be targeted using traditional Chimeric Antigen Receptor (CAR)-T cells limited to surface antigens. Since NB is driven by epigenetically .... Traditional CARs bind directly to antigens expressed on the outer surface of cancer cells. However, many critical cancer-driving proteins reside within the cell. These intracellular oncoproteins can be processed into small peptide fragments, which are then presented on the cell surface by HLA molecules. PC-CARs are specifically designed to detect these peptide-HLA complexes, effectively "seeing" and attacking cancer cells based on their intracellular protein abnormalities.
This peptide-centric approach has opened up new avenues for targeting a diverse array of tumor antigens that were once considered undruggableStructural principles of peptide-centric Chimeric Antigen .... Researchers have focused on developing PC-CARs for specific intracellular oncoproteins, such as PHOX2B in neuroblastoma and mutant KRAS, which are implicated in various aggressive cancers.
The development of PC-CARs has shown particular promise in treating solid tumors and hematological malignancies. One of the most notable applications has been in the treatment of neuroblastoma, a childhood cancer driven by intracellular oncoproteins.Targeting of intracellular oncoproteins with peptide-centric ... Studies have demonstrated that PC-CAR T cells engineered to target the PHOX2B oncoprotein can effectively and selectively eliminate neuroblastoma tumors in preclinical models. This success highlights the potential of PC-CARs to overcome the limitations of traditional CAR T-cell therapy in solid tumors, which often struggle with antigen heterogeneity and accessibility.2021年11月4日—Tests showed that a neuroblastomapeptide-targeting PC-CARcompletely and selectively eliminated neuroblastoma tumors in mice.
Beyond neuroblastoma, the technology is being explored for other challenging cancers. Research into targeting mutant KRAS peptides, a common driver in many difficult-to-treat cancers like pancreatic, lung, and colorectal cancers, is another active area. By recognizing specific KRAS peptide fragments presented by HLAs, PC-CARs could offer a new therapeutic option for patients with these malignancies.
A significant challenge in developing targeted immunotherapies is HLA restriction.作者：Y Sun·2023·被引用次数：17—Peptide-centricchimeric antigen receptors (PC-CARs) recognize oncoprotein epitopes displayed by cell-surface human leukocyte antigens (HLAs) ... HLA molecules are highly diverse among individuals, meaning a therapy that works for one patient might not work for another due to differences in their HLA types. Early PC-CAR designs often targeted specific peptide-HLA combinations. However, recent advancements have focused on developing PC-CARs capable of cross-HLA targeting.作者：GK Griffin·2022·被引用次数：1—MHC-peptides derived from intracellular oncoproteins represent novel CAR-T targets in pediatric neuroblastoma ...peptide-centric CARs. Nature 599 ... This means a single PC-CAR can recognize a specific peptide presented by multiple different HLA alleles. This broader recognition capability is crucial for increasing the number of patients who can benefit from this therapy, as it reduces the dependency on a patient's unique HLA makeup2021年11月3日—Thepeptide-centric CART cells, or PC-CARS, target cancer drivers in tumor cells previously thought unreachable..
The field of peptide-centric CARs is rapidly evolving, with ongoing research aimed at refining their design, enhancing their efficacy, and expanding their therapeutic reach作者：M Yarmarkovich·被引用次数：114—These data suggest thatpeptide-centric CARshave the potential to vastly expand the pool of immunotherapeutic targets to include non .... Key areas of focus include:
* Improving Specificity: Ensuring PC-CARs accurately target cancer cells while minimizing off-target effects on healthy tissues is paramount.
* Broadening HLA Coverage: Continued development of CARs that can recognize a wider array of HLA types will be essential for widespread clinical application.
* Clinical Translation: Moving promising preclinical findings into human clinical trials is the next critical step(PDF) Cross-HLA targeting of intracellular oncoproteins .... Early trials are already underway for specific PC-CAR therapies, such as those targeting PHOX2B for relapsed neuroblastomaPeptide-Centric CAR Construction Service.
While PC-CARs offer immense potential, challenges remain. Understanding the complex interplay between tumor peptides, HLA presentation, and T-cell activation is crucial....peptide-centric CARs(PC-CARs). We have discovered the ability of PC-CARs to target peptides across multiple HLA types, significantly expanding the patient ... Furthermore, the manufacturing and regulatory pathways for these highly engineered cell therapies require careful navigationBy discovering scFvs that are highly specific for the peptide in the MHC groove,peptide-centric CAR(PC-CAR) T cells cured mice of highly aggressive patient- ....
In conclusion, peptide-centric CARs represent a groundbreaking development in cancer immunotherapyNew Kind of CAR T-Cell Changes Scientists' Approach to .... By enabling the targeting of intracellular oncoproteins through their peptide fragments presented on HLAs, PC-CARs are poised to overcome major limitations of existing therapies and offer new hope for patients battling a wide spectrum of cancers.
Join the newsletter to receive news, updates, new products and freebies in your inbox.